Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or Oropharynx

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00002702
Recruitment Status : Unknown
Verified February 2011 by National Cancer Institute (NCI).
Recruitment status was:  Recruiting
First Posted : January 27, 2003
Last Update Posted : August 26, 2013
Information provided by:
National Cancer Institute (NCI)

Brief Summary:

RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells of the mouth or oropharynx. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not known whether giving interleukin-2 with surgery and radiation therapy is more effective than surgery and radiation therapy alone.

PURPOSE: This randomized phase III trial is studying surgery and radiation therapy alone to see how well they work compared to surgery, radiation therapy, and interleukin-2 in treating patients with cancer of the mouth or oropharynx.

Condition or disease Intervention/treatment Phase
Head and Neck Cancer Biological: aldesleukin Procedure: adjuvant therapy Procedure: conventional surgery Procedure: neoadjuvant therapy Radiation: radiation therapy Phase 3

Detailed Description:


  • Compare the disease-free and overall survival in patients with previously untreated squamous cell carcinoma of the oral cavity or oropharynx treated with resection with or without and neoadjuvant and adjuvant perilymphatic interleukin-2 (IL-2) and radiotherapy.
  • Compare the response rate in patients treated with these regimens.
  • Determine the local and systemic effects of locoregional IL-2 on host-tumor interaction and immune properties in these patients.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to center and tumor stage (T2, N0-2 vs T2, N3 or T3-4, N0-3). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients undergo induction comprising interleukin-2 (IL-2) via perilymphatic injections to the ipsilateral myelohyoid muscle and insertion of the sternocleidomastoid muscle on days 1-5 and 8-12. Within 10 days after the last IL-2 injection, patients undergo en bloc resection of the primary tumor and corresponding lymphatic drainage area and pre-study margins. Beginning within 4 weeks after surgery, patients with T2, N0-3 disease but with pathohistological evidence of node invasion or capsular rupture of node metastasis or T3-4, N0-3 disease undergo adjuvant radiotherapy 5 days a week for 4.5-6.5 weeks. Beginning within 4 weeks after surgery or radiotherapy (if applicable), patients receive adjuvant IL-2 via perilymphatic injections to the contralateral myelohyoid muscle and insertion of the sternocleidomastoid muscle on days 1-5. Adjuvant IL-2 continues monthly for at least 1 year in the absence of disease progression.
  • Arm II: Patients undergo resection and radiotherapy (if eligible) as in arm I. Patients are followed monthly for 1 year and then every 2 months for 2 years.

PROJECTED ACCRUAL: A total of 260 patients (130 per treatment arm) will be accrued for this study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 260 participants
Allocation: Randomized
Primary Purpose: Treatment
Official Title: Multicentre Randomised Trial of Inductive and Adjuvant Perilymphatically Injected Proleukin (rlL-2) in The Treatment of Operable Primary Squamous Cell Carcinoma of The Oral Cavity and Oropharynx
Study Start Date : September 1992

Resource links provided by the National Library of Medicine

Drug Information available for: Aldesleukin

Primary Outcome Measures :
  1. Disease-free survival at 3 and 5 years
  2. Recurrence/metastasis rate at 3 and 5 years
  3. Response rate
  4. Local and systemic effects of treatment

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   up to 75 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically proven squamous cell carcinoma of the oral cavity or oropharynx

    • Operable, primary, unilateral, stage T2-4, N0-3, M0 disease
    • No high probability of bilateral lymphatic spread (requirement for bilateral neck dissection)
  • No tumor involvement of the following sites:

    • Pterygopalatine fossa
    • Carotid artery
    • Maxillary sinus
    • Facial skin
    • Anterior floor of the mouth
    • Base of the tongue infiltrating more than 1 cm
  • Measurable or evaluable disease by physical exam and/or noninvasive imaging



  • 75 and under

Performance status:

  • ECOG 0-2 OR
  • Karnofsky 70-100%

Life expectancy:

  • More than 3 months


  • WBC at least 4,000/mm3
  • Platelet count at least 60,000/mm3
  • Hematocrit at least 30%


  • Bilirubin normal
  • Hepatitis B surface antigen negative


  • Creatinine normal


  • No congestive heart failure
  • No uncontrolled hypertension
  • No coronary artery disease
  • No serious arrhythmia
  • No evidence of prior myocardial infarction on ECG (stress test required if in doubt)


  • HIV negative
  • No autoimmune disease
  • No contraindications to pressor agents
  • No serious infection requiring antibiotics
  • No other concurrent primary malignancy
  • Not pregnant or nursing


Biologic therapy:

  • No prior or other concurrent immunotherapy


  • No prior or concurrent chemotherapy

Endocrine therapy:

  • No prior or concurrent hormonal therapy
  • No concurrent corticosteroids


  • No prior radiotherapy


  • See Disease Characteristics
  • No prior major organ allografts


  • No other prior therapy
  • No other concurrent investigational drugs, agents, or devices
  • No concurrent nonsteroidal antiinflammatory drugs, ranitidine, cimetidine, or coumarin

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00002702

Layout table for location information
Universita Degli Studi di Bari Recruiting
Bari, Italy, 70124
Contact: G. Cervellera, MD    39-080-5478-660      
Cattedra di Oncologia Medica - Universita degli Studi di Cagliari Recruiting
Cagliari, Italy, 09042
Contact: P. Puxeddu, MD    39-070-5109-6253      
Universita di Ferrara Recruiting
Ferrara, Italy, 44100
Contact: C. Calearo, MD    39-0532-209-296   
Universita Degli Studi di Florence - Policlinico di Careggi Recruiting
Florence, Italy, 50134
Contact: O. Fini-Storchi, MD    39-55-411739      
Universita di Torino Recruiting
Turin, Italy, 10126
Contact: G. Valente, MD    39-011-670-5955      
Azienda Sanitaria Ospedaliera Ordine Mauriziano Recruiting
Turin, Italy, 10128
Contact: G. Forni, MD    39-11-508-1111      
Ospedale San Bortolo Recruiting
Vicenza, Italy, 36100
Contact: C. Curioni, MD    39-444-993-906      
Sponsors and Collaborators
European Institute of Oncology
Layout table for investigator information
Study Chair: Giorgio Cortesina, MD Universita Degli Studi di Turin

Layout table for additonal information Identifier: NCT00002702    
Other Study ID Numbers: CDR0000064500
First Posted: January 27, 2003    Key Record Dates
Last Update Posted: August 26, 2013
Last Verified: February 2011
Keywords provided by National Cancer Institute (NCI):
stage II squamous cell carcinoma of the lip and oral cavity
stage III squamous cell carcinoma of the lip and oral cavity
stage IV squamous cell carcinoma of the lip and oral cavity
stage II squamous cell carcinoma of the oropharynx
stage III squamous cell carcinoma of the oropharynx
stage IV squamous cell carcinoma of the oropharynx
tongue cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Head and Neck Neoplasms
Neoplasms by Site
Antineoplastic Agents
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents